Skip to main navigation menu Skip to main content Skip to site footer

Author reply to technical comment

Vol. 149 No. 3940 (2019)

Reply to comment by Carratù P, et al. on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

  • Katrin E. Hostettler
  • Martin H. Brutsche
DOI
https://doi.org/10.4414/smw.2019.20133
Cite this as:
Swiss Med Wkly. 2019;149:w20133
Published
30.09.2019

References

  1. Carratù P, Dragonieri S, Resta O. Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2019;149:w20132. doi:https://doi.org/10.4414/smw.2019.20132
  2. Hostettler K, Baty F, Kleiner R, Junker L, Tamm M, Brutsche M. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2018;148:w14677. doi:.https://doi.org/10.4414/smw.2018.14677
  3. Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995;12(2):118–23.

Most read articles by the same author(s)